AZIS R. DABAS

Healthcare strategy
AI + operating leadership

Operating recordMandates
Index
Let’s talk
← InsightsPUBLISHED ANALYSIS
Insight / Operator brief

340B Is Becoming a Claims-Data Operating Problem

Mineral discs linked by a fine thread and a sequence of suspended droplets
Coordinated flowTherapy & transactions

CMS's proposed Part D claim-level data requirements make 340B traceability a cross-functional operating issue spanning pharmacy, provider, claims, contract pharmacy, finance, compliance, and rebate workflows.

Return to insights

340B covered entities, specialty pharmacy leaders, provider finance teams, claims platforms, compliance leaders, and healthtech founders / 2026-07-19

By Healthcare growth and AI operations executive

Founder question

Can the organization produce one defensible claim history when pharmacy, provider, payer, manufacturer, and repository records do not naturally live in the same system?

Public factsOperator interpretationBuyer implicationsFounder action

The claim-level requirement discussed here is proposed. This brief is operating analysis, not 340B, billing, rebate, or legal advice.

Executive thesis

Source-backed operator read.

340B data is moving toward more granular traceability inside Medicare drug-payment operations. That turns what can look like a pharmacy compliance topic into a broader operating-system problem: identity, claim status, covered-entity and contract-pharmacy relationships, reversals, corrections, source authority, financial reconciliation, and audit evidence must agree. The strategic opportunity is not another dashboard. It is a defensible claim object and exception workflow that finance, pharmacy, compliance, and operations can share.

Public facts

  1. In the CY 2027 Physician Fee Schedule proposed rule, CMS proposes that 340B covered entities submit certain claim-level data for covered Part D drugs billed to Medicare Part D and dispensed by the entity or its contract pharmacies for dates of service on or after January 1, 2027.

  2. CMS links the proposed data collection to administration of the Medicare Prescription Drug Inflation Rebate Program.

  3. CMS's inflation-rebate program page identifies the July 2026 proposed rulemaking and a September 14, 2026 comment deadline.

Operator read

  1. The policy pressure exposes a familiar operating gap: records are distributed across organizations and systems, but accountability lands on a claim-level answer.

  2. The valuable product is reconciliation and exception resolution, not aggregation alone. A dashboard that cannot explain conflicts will fail at audit time.

  3. Commercial design must recognize that pharmacy, finance, compliance, and IT have different definitions of completion and risk.

  4. The same architecture can create broader revenue-integrity value if identity, provenance, reversals, and adjustments are reliable.

Operating model

Turn the thesis into a decision system.

The framework defines the work; the metrics define whether the work is creating value.

Operating framework

  1. 01

    Create a claim-level data contract linking drug, beneficiary, prescriber, covered entity, dispensing entity, date of service, payer, and 340B status.

  2. 02

    Define source authority, timing, validation, correction, and exception ownership for every field.

  3. 03

    Reconcile contract-pharmacy, accumulator, switch, PBM, provider, and finance records into one auditable object.

  4. 04

    Separate operational exceptions from compliance determinations and route both to named owners.

  5. 05

    Measure completeness, timeliness, correction burden, and financial exposure before submission deadlines.

Metrics that matter

  1. 01

    Claim-level match and completeness rate

  2. 02

    Time to resolve status conflicts

  3. 03

    Submission rejection and correction rate

  4. 04

    Unreconciled financial exposure

  5. 05

    Audit retrieval time and evidence completeness

Buyer implications

  1. Covered entities should inventory data lineage and exception ownership before the proposed effective date.

  2. Vendors should prove claim-level reconciliation, correction, audit retrieval, and role-based controls.

  3. Finance leaders should quantify unresolved exposure rather than relying on aggregate confidence.

Founder actions

  1. Map every source, field, owner, timing rule, and reconciliation key.

  2. Build a representative exception set including reversals, duplicates, contract-pharmacy mismatches, and late corrections.

  3. Create a shared claim object with provenance and a complete action history.

  4. Pilot the operating workflow with pharmacy, compliance, finance, and IT in the same review cadence.

Red flags

  1. 340B status is inferred from aggregate reports rather than supported at claim level.

  2. Contract-pharmacy and covered-entity records cannot be reconciled on a consistent key.

  3. Finance, compliance, and pharmacy use different exception definitions.

CEO and CFO questions

  1. Which system is authoritative for each required data element?

  2. How are duplicate, reversed, adjusted, and unmatched claims handled?

  3. Who owns correction before the data reaches CMS or another counterparty?

  4. What financial exposure remains outside the reconciled dataset?

Government payment integrity and policy workflowAI solutions design and RCM orchestrationFounder-to-exit specialty pharmacyGovernment payment integrity and policy workflowAI solutions design and RCM orchestrationFounder-to-exit specialty pharmacyGovernment payment integrity control plane

Build one auditable data, reconciliation, exception, and financial workflow across the 340B operating system.

Map the claim-level control plane

Start a serious conversation

Use the market signal before it becomes consensus.

Discuss an operating mandate